HLA-DMB

Across TCGA pan-cancer cohorts, HLA-DMB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HLA-DMB data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher HLA-DMB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-DMB expression acts as an unfavorable survival marker.

LGG, UCEC, and PRAD are the cancer types where HLA-DMB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.242	0.801	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
THCA	DFS	Median	All	0.224	0.843	.022	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HLA-DMB–LGG (OS)

Open the LGG breakdown →